Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07301008 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US

Study acronym: RIM
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 24, 2025 (before its estimated September 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
Single-center, open label, prospective study conducted at Medstar Georgetown Headache Center. Men and woman ≥ 18 years old that are diagnosed with migraine with or without aura for at least 1 year, who report a reliable migraine trigger. Acceptable triggers for the study will include exercise, alcohol (less than one drink per day for woman and less than two drinks per day for men), air travel that lasts no more than 12 hours, sexual activity, fasting that lasts no more than 24 hours, stress or stress let-down headache.
Trial Details
NCT Number NCT07301008
Lead Sponsor Medstar Health Research Institute
Collaborators: Pfizer
Conditions
(from sponsor)		 Migraine, Trigger Induced Migraine
Related terms Migraine Disorders
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov